{
  "@context": {
    "biotools": "https://bio.tools/ontology/",
    "bsc": "http://bioschemas.org/",
    "edam": "http://edamontology.org/",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@id": "https://bio.tools/ADNI-3",
  "@type": "sc:SoftwareApplication",
  "sc:description": "> CORRECT NAME OF TOOL COULD ALSO BE 'AD N', 'associated dementia', 'thevirtualbrain.org neuroinformatics', 'Virtual Brain' | Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease | Alzheimer's Disease Neuroimaging Initiative | Alzheimer’s Disease Neuroimaging Initiative | ADNI3 began in 2016 and includes scientists at 59 research centers in the United States and Canada. Between 1070-2000 participants will be enrolled: approximately 700-800 rollover participants from ADNI2 and 370-1200 newly enrolled subjects. Clinical, cognitive, imaging, biomarker and genetic characteristics will be assessed across three cohorts: Cognitively normal, MCI and mild AD dementia | The Alzheimer’s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer’s disease (AD)",
  "sc:name": "ADNI-3",
  "sc:url": "http://adni.loni.usc.edu"
}